Home Newsfeeds Oppenheimer Downgrades Unity Software to Perform

Oppenheimer Downgrades Unity Software to Perform

Oppenheimer analyst Martin Yang downgrades Unity Software (NYSE:U) from Outperform to Perform.

byBenzinga Newsdesk

February 23, 2023

1 minute read

Oppenheimer analyst Martin Yang downgrades Unity Software (NYSE:U) from Outperform to Perform.

Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs

By Benzinga Newsdesk

December 19, 9:41 AM

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"),

IKT

Jefferies Initiates Coverage On United Parcel Service with Buy Rating, Announces Price Target of $190

By Benzinga Newsdesk

October 25, 5:08 AM

Jefferies analyst Stephanie Moore initiates coverage on United Parcel Service (NYSE:UPS) with a Buy rating and announces Price Target of $190.

UPS

Bloom Energy Q3 EPS $(0.20) Misses $(0.06) Estimate, Sales $292.30M Beat $277.20M Estimate

By Benzinga Newsdesk

November 3, 4:53 PM

Bloom Energy (NYSE:BE) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.06) by 233.33 percent. This is unchanged from the same period last year. The company reported

Bio-Techne President, Diagnostics and Genomics Segment, Kim Kelderman to Lead as CEO Effective February 1

By Benzinga Newsdesk

January 5, 8:11 AM

Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim

TECH

Oppenheimer Downgrades Unity Software to Perform

Related Posts

Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs

Jefferies Initiates Coverage On United Parcel Service with Buy Rating, Announces Price Target of $190

Bloom Energy Q3 EPS $(0.20) Misses $(0.06) Estimate, Sales $292.30M Beat $277.20M Estimate

Bio-Techne President, Diagnostics and Genomics Segment, Kim Kelderman to Lead as CEO Effective February 1